Valeant confirms $8.7bn purchase of Bausch + Lomb
This article was originally published in Scrip
Executive Summary
As widely anticipated, Canada's Valeant Pharmaceuticals International has signed a definitive agreement to acquire Bausch + Lomb Holdings, for which it will pay $8.7 billion in cash financed through a combination of debt and new equity.
You may also be interested in...
Finance Watch: Brent Saunders Plots Return To Deal-Making With A SPAC IPO
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.